QCLS - MyMD Pharmaceuticals, Inc.
4.5
1.020 22.667%
Share volume: 10,947,143
Last Updated: 03-06-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$3.48
1.02
0.29%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-15-2024 | 08-19-2024 | 11-14-2024 | 05-15-2025 | 08-19-2025 | 11-19-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | |||
| Operating expenses | 2.267 M | 1.421 M | 1.812 M | 2.387 M | 1.768 M | 1.324 M | |
| Selling general and admin | 1.068 M | 1.020 M | 1.104 M | 841.685 K | 894.297 K | 967.833 K | |
| Research and development | 1.199 M | 401.104 K | 707.747 K | 1.546 M | 873.472 K | 356.352 K | |
| Total expenses | 2.785 M | 3.370 M | 1.826 M | 2.472 M | 1.873 M | 1.789 M | |
| 21.01% | -45.82% | 35.40% | -24.24% | -4.48% | |||
| Operating income | -2.785 M | -3.370 M | -1.826 M | -2.472 M | -1.873 M | -1.789 M | |
| Ebit | -9.818 M | -9.587 M | -2.093 M | -1.189 M | -1.854 M | -2.847 M | |
| Pretax income | -9.800 M | -9.566 M | -1.929 M | -1.125 M | -1.796 M | -2.811 M | |
| -2.39% | -79.83% | -41.70% | 59.70% | 56.52% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -9.800 M | -9.566 M | -1.929 M | -1.125 M | -1.796 M | -2.811 M | |
| 2.39% | 79.83% | 41.70% | -59.70% | -56.52% |